Administration of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy; a new strategy in the management?

Some of the several effects sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According recent studies regarding beneficial SGLT-2i on IgAN, it is clear that are changing approach towards transplantation when comes aggressive immunosuppression. This mini-review aims evaluation efficacy IgA-nephropathy.